Who or what is your inspiration in business?

AmritaGen, based in Fort Worth, Texas, conducts research on Alzheimer’s disease with the goal of developing new therapies. The company focuses on creating innovative medicines using proprietary genetically engineered exosome technologies to deliver drugs across the blood–brain barrier. AmritaGen is advancing a novel gene therapy approach that enables combination drug delivery for neurodegenerative diseases. Alzhemers' drug clinical trials fail because they cannot cross the blood brai

How do you stay motivated?

Our motivation comes from the fact that Alzheimer’s disease remains a major challenge to medicine. For the past ten years, we have worked to identify combiGene targets that link the initiation and progression of sporadic AD. The global Alzheimer’s market may reach $25 billion by 2027, driven by aging populations and improved diagnostics. Yet our goal is not only revenue, but improving lives. Watching loved ones decline from Alzheimer’s fuels our commitment to develop effective

What would you do with the $25,000?

AmritaGen will use the $25,000 to run key experiments needed to generate data for grant submissions and investor funding. We have already completed exosome studies in mice and successfully delivered green fluorescent protein to the brain by bypassing the blood–brain barrier. Our next step is to conduct similar studies in primates to further validate the technology. This funding would significantly accelerate our progress and strengthen our ability to secure larger investments.